[go: up one dir, main page]

CY1112477T1 - Φαρμακευτικο παρασκευασμα που εχει εξαιρετικh φωτοσταθεροτητα - Google Patents

Φαρμακευτικο παρασκευασμα που εχει εξαιρετικh φωτοσταθεροτητα

Info

Publication number
CY1112477T1
CY1112477T1 CY20121100247T CY121100247T CY1112477T1 CY 1112477 T1 CY1112477 T1 CY 1112477T1 CY 20121100247 T CY20121100247 T CY 20121100247T CY 121100247 T CY121100247 T CY 121100247T CY 1112477 T1 CY1112477 T1 CY 1112477T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical preparation
pitavastatin
light stability
extremely light
hmg
Prior art date
Application number
CY20121100247T
Other languages
English (en)
Inventor
Masato Kozaki
Yoshio Tanizawa
Hiroyuki Kawashima
Original Assignee
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Company, Ltd. filed Critical Kowa Company, Ltd.
Publication of CY1112477T1 publication Critical patent/CY1112477T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε φαρμακευτικό παρασκεύασμα υψηλής φωτοσταθερότητας που περιέχει πιταβαστατίνη, που είναι ένας αναστολέας αναγωγάσης ΗΜG-CoA, άλας πιταβαστατίνης ή εστέρα πιταβαστατίνης. Το φαρμακευτικό παρασκεύασμα περιέχει ένωση πιταβαστατίνης, οξείδιο τιτανίου και ένα χρωματιστικό που έχει μέγιστη απορρόφηση μήκους κύματος 400 nm έως 500 nm.
CY20121100247T 2005-10-31 2012-03-09 Φαρμακευτικο παρασκευασμα που εχει εξαιρετικh φωτοσταθεροτητα CY1112477T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005316758 2005-10-31
EP06822589A EP1944029B1 (en) 2005-10-31 2006-10-30 Pharmaceutical preparation having excellent photostability

Publications (1)

Publication Number Publication Date
CY1112477T1 true CY1112477T1 (el) 2015-12-09

Family

ID=38005744

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100247T CY1112477T1 (el) 2005-10-31 2012-03-09 Φαρμακευτικο παρασκευασμα που εχει εξαιρετικh φωτοσταθεροτητα

Country Status (23)

Country Link
US (1) US20090041843A1 (el)
EP (1) EP1944029B1 (el)
JP (3) JP5166876B2 (el)
KR (1) KR101409087B1 (el)
CN (1) CN101300010B (el)
AT (1) ATE537827T1 (el)
AU (1) AU2006309826B2 (el)
CA (1) CA2626309A1 (el)
CY (1) CY1112477T1 (el)
DK (1) DK1944029T3 (el)
EA (1) EA016713B1 (el)
ES (1) ES2375643T3 (el)
IL (1) IL190346A (el)
NO (1) NO20081526L (el)
NZ (1) NZ566872A (el)
PL (1) PL1944029T3 (el)
PT (1) PT1944029E (el)
SG (1) SG196789A1 (el)
SI (1) SI1944029T1 (el)
TW (1) TWI422375B (el)
UA (1) UA92920C2 (el)
WO (1) WO2007052592A1 (el)
ZA (1) ZA200803655B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
JP5591128B2 (ja) * 2009-01-29 2014-09-17 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
JP2012041290A (ja) * 2010-08-18 2012-03-01 Sawai Pharmaceutical Co Ltd ラフチジン含有固形製剤
JP5809467B2 (ja) * 2011-07-12 2015-11-11 エルメッド エーザイ株式会社 ピタバスタチン含有組成物及びその製造方法
JP5844574B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する安定化された薬物組成物
JP5844573B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する錠剤
TWI636783B (zh) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
WO2014024268A1 (ja) 2012-08-08 2014-02-13 興和株式会社 医薬
SMT202000190T1 (it) 2013-06-06 2020-05-08 Fibrogen Inc Formulazioni farmaceutiche di un inibitore di hif-idrossilasi
JP6150703B2 (ja) * 2013-10-08 2017-06-21 ダイト株式会社 ピタバスタチンカルシウム塩の分解抑制方法
JP6243265B2 (ja) * 2014-03-20 2017-12-06 日医工株式会社 ロスバスタチン含有医薬製剤
JP6433400B2 (ja) * 2014-09-30 2018-12-05 株式会社三和化学研究所 ＨＭＧ−ＣｏＡレダクターゼ阻害薬を含有する医薬製剤
CN104367560A (zh) * 2014-10-23 2015-02-25 万全万特制药江苏有限公司 一种新型匹伐他汀钙口腔崩解片组合物及其制备方法
ES2766424T3 (es) 2015-03-19 2020-06-12 Daiichi Sankyo Co Ltd Preparación sólida que contienen agente oxidante
KR102401145B1 (ko) * 2015-03-19 2022-05-23 다이이찌 산쿄 가부시키가이샤 착색제를 함유하는 고형 제제
JP6072884B2 (ja) * 2015-11-19 2017-02-01 共和薬品工業株式会社 ピタバスタチンを含有する製剤
KR102602820B1 (ko) 2017-01-30 2023-11-15 시오노기세이야쿠가부시키가이샤 퀴나졸린 유도체를 함유하는 고형 제제
TWI795462B (zh) 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
CN108543075A (zh) * 2018-04-29 2018-09-18 广东伊茗药业有限公司 一种光稳定性优异的医药制剂
KR20210038414A (ko) 2018-07-30 2021-04-07 다이이찌 산쿄 가부시키가이샤 안정화제를 함유하는 의약품의 고형 제제
EA202191371A1 (ru) * 2018-12-14 2021-12-27 Фуджифилм Корпорэйшн Фармацевтическая композиция и способ ее получения
CN112402388A (zh) * 2019-08-05 2021-02-26 江苏亚虹医药科技股份有限公司 一种用于治疗膀胱癌的口服固体制剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU432703A3 (el) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
JPS5522645A (en) * 1978-08-07 1980-02-18 Fujisawa Pharmaceut Co Ltd Soft capsule for encapsulation of light-unstable compound
JPS6059205B2 (ja) * 1981-12-24 1985-12-24 帝三製薬株式会社 光不安定性薬物を包容するための軟カプセルの製造方法
JPS61275214A (ja) * 1985-05-28 1986-12-05 Sawai Seiyaku Kk 経口用メナテトレノン軟カプセル
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
DE4446470A1 (de) * 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von teilbaren Tabletten
US6465477B1 (en) * 1997-08-18 2002-10-15 Kowa Company, Ltd. Stable pharmaceutical composition
EP0901787B1 (en) * 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
JP2000191516A (ja) * 1998-10-23 2000-07-11 Taisho Pharmaceut Co Ltd 経口固形組成物
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
JP2003104887A (ja) * 2001-09-28 2003-04-09 Maruko Seiyaku Kk 光に安定なアラニジピン含有組成物
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
JP5008565B2 (ja) * 2004-05-21 2012-08-22 アキュ−ブレイク テクノロジーズ インコーポレーテッド 相対的に不活性なセグメントを有する医薬錠剤
BRPI0609636B8 (pt) * 2005-04-08 2021-05-25 Abbott Lab formulação oral de liberação modificada que compreende um agente ativo e um revestimento entérico

Also Published As

Publication number Publication date
EP1944029A4 (en) 2011-01-12
UA92920C2 (ru) 2010-12-27
JP2013014610A (ja) 2013-01-24
ZA200803655B (en) 2009-10-28
CA2626309A1 (en) 2007-05-10
PL1944029T3 (pl) 2012-05-31
JP5166876B2 (ja) 2013-03-21
HK1124772A1 (en) 2009-07-24
KR101409087B1 (ko) 2014-06-17
EA200800993A1 (ru) 2008-08-29
SI1944029T1 (sl) 2012-03-30
EP1944029A1 (en) 2008-07-16
KR20080058449A (ko) 2008-06-25
WO2007052592A1 (ja) 2007-05-10
ATE537827T1 (de) 2012-01-15
JP5677391B2 (ja) 2015-02-25
NZ566872A (en) 2010-12-24
ES2375643T3 (es) 2012-03-02
CN101300010B (zh) 2012-06-06
IL190346A (en) 2013-06-27
AU2006309826A1 (en) 2007-05-10
EP1944029B1 (en) 2011-12-21
IL190346A0 (en) 2009-09-22
DK1944029T3 (da) 2012-01-23
PT1944029E (pt) 2012-02-09
SG196789A1 (en) 2014-02-13
JPWO2007052592A1 (ja) 2009-04-30
TWI422375B (zh) 2014-01-11
JP2012246325A (ja) 2012-12-13
US20090041843A1 (en) 2009-02-12
CN101300010A (zh) 2008-11-05
TW200800191A (en) 2008-01-01
NO20081526L (no) 2008-07-29
AU2006309826B2 (en) 2012-01-19
EA016713B1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
CY1112477T1 (el) Φαρμακευτικο παρασκευασμα που εχει εξαιρετικh φωτοσταθεροτητα
IL183962A0 (en) Fluorescent pyrazine derivatives and methods of using the same in assessing renal function
CY1115462T1 (el) ΣΥΝΔΥΑΣΜΟΣ ΑΝΑΣΤΟΛΕΩΝ ΗΜG-CoΑ ΑΝΑΓΩΓΑΣΗΣ ΑΤΟΡΒΑΣΤΑΤΙΝΗΣ Ή ΣYΜΒΑΣΤΑΤΙΝΗΣ ΜΕ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΔΙΕΣΤΕΡΑΣΗΣ 4 ΟΠΩΣ ΡΟΦΛΟΥΜΙΛΑΣΤΗ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΦΛΕΓΜΟΝΩΔΩΝ ΠΝΕΥΜΟΝΙΚΩΝ ΑΣΘΕΝΕΙΩΝ
WO2005034790A3 (en) Use of secondary optical emission as a novel biofilm targeting technology
DE60307122D1 (de) Synergistische uv-absorber-kombination
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
DE602005008953D1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
EA200800070A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина
WO2009044873A1 (ja) 光学ガラス及びこれを使用した光学装置
BRPI0412636A (pt) imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
FR2896158B1 (fr) Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
ATE489936T1 (de) Zusammensetzung mit mindestens einem c-glycosid- derivat und mindestens einer hyaluronsäure sowie ihre kosmetische anwendung
DK1879862T3 (da) Magnesiumsalte af HMG-COA reduktaseinhibitorer
IL190024A0 (en) Stabilized protease composition
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
WO2005025491A3 (en) Water-soluble polyamioamides as sunscreen agents
DE60233899D1 (de) Neue boronatester
BR0200536A (pt) Compostos de sulfonilpiridazinana úteis como inibidores de aldose reductase
EP2724705A3 (en) Dental visible-light curable composition and method of identifying presence of same
DE60325589D1 (de) Pigmentprotein
ATE511830T1 (de) Lichtschutzzubereitung mit mikropigmenten
MA31206B1 (fr) Dérivés cyclohexyl amide d'acide carboxylique aryle
EA200501499A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ п-ДИАМИНОБЕНЗОЛА
WO2006027344A3 (en) 3-oxa-10-aza-phenanthrenes as pde4 or pde3/4 inhibitors
AR054532A1 (es) Derivados heteroariletenilo su obtencion y utilizacion como agentes farmaceuticos